1. Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study
- Author
-
Vicentini, Massimo, Zorzi, Manuel, Bovo, Emanuela, Mancuso, Pamela, Zappa, Marco, Manneschi, Gianfranco, Mangone, Lucia, Rossi, Paolo Giorgi, Grazzini, Grazia, Mantellini, Paola, Caldarella, Adele, Intrieri, Teresa, Anghinoni, Emanuela, Senore, Carlo, Tisano, Francesco, Ziino, Antonio Colanino, Malignaggi, Sabina, Passanisi, Guido, Rugge, Massimo, Turrin, Anna, Piffer, Silvano, Gentilini, Maria, Rizzello, Roberto, Pertile, Riccardo, Sensi, Flavio, Cesaraccio, Rosaria, Interieri, Teresa, Ferretti, Stefano, Collina, Natalina, Petrucci, Chiara, Fanetti, Anna Clara, Cecconami, Lorella, Fusco, Mario, Vitale, Maria Francesca, Castaing, Marine, Ippolito, Antonella, Varvara, Massimo, Pesce, Paola, Filiberti, Rosa, Borciani, Elisabetta, Seghini, Pietro, Stracci, Fabrizio, Malaspina, Morena, Serraino, Diego, Falcini, Fabio, Giuliani, Orietta, Pannozzo, Fabio, Curatella, Simonetta, Calabretta, Francesca, Bellardini, Paola, Carrozzi, Giuliano, Bisanti, Luigi, Russo, Antonio Giampiero, Silvestri, Anna Rita, Tidone, Enrica, Giacomin, Adriano, Azzoni, Alberto, Mazzucco, Walter, Cusimano, Rosanna, Campari, Cinzia, Caroli, Stefania, Michiara, Maria, Sgargi, Paolo, De Togni, Aldo, Palmonari, Caterina, Casella, Claudia, Puppo, Antonella, Vicentini M., Zorzi M., Bovo E., Mancuso P., Zappa M., Manneschi G., Mangone L., Rossi P.G., Grazzini G., Mantellini P., Caldarella A., Intrieri T., Anghinoni E., Senore C., Tisano F., Ziino A.C., Malignaggi S., Passanisi G., Rugge M., Turrin A., Piffer S., Gentilini M., Rizzello R., Pertile R., Sensi F., Cesaraccio R., Interieri T., Ferretti S., De Togni A., Palmonari C., Collina N., Petrucci C., Fanetti A.C., Cecconami L., Fusco M., Vitale M.F., Castaing M., Ippolito A., VarvarA M., Pesce P., Filiberti R., Casella C., Puppo A., Borciani E., Seghini P., Stracci F., Malaspina M., Serraino D., Falcini F., Giuliani O., Pannozzo F., Curatella S., Calabretta F., Bellardini P., Carrozzi G., Bisanti L., Russo A.G., Silvestri A.R., Tidone E., Giacomin A., Azzoni A., Mazzucco W., Cusimano R., Campari C., Caroli S., Michiara M., and Sgargi P.
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,Prevalence ,Socio-culturale ,Colonoscopy ,Colorectal Neoplasm ,Settore MED/42 - Igiene Generale E Applicata ,colorectal cancer screening ,Screening programme ,Feces ,03 medical and health sciences ,0302 clinical medicine ,colonoscopy ,Faecal immunochemical test, colonoscopy, colorectal cancer screening, epidemiology, cancer registries ,Internal medicine ,Epidemiology ,medicine ,Humans ,Stage (cooking) ,Early Detection of Cancer ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,cancer registrie ,medicine.diagnostic_test ,Faecal immunochemical test ,business.industry ,Incidence (epidemiology) ,Incidence ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Oncology ,Italy ,cancer registries ,030220 oncology & carcinogenesis ,Relative risk ,Occult Blood ,epidemiology ,Fece ,Female ,Neoplasm Grading ,Colorectal Neoplasms ,business ,Human - Abstract
To evaluate the impact of faecal immunochemical test (FIT) screening on stage distribution at diagnosis, and to estimate relative incidence rates by stage in screened at first and subsequent rounds vs. unscreened. We included all incident cases occurring in 2000-2008 in 50- to 71-year-olds residing in areas with an FIT-screening programme. Multinomial logistic models were computed to estimate the relative risk ratio (RRR) of stages I and IV, compared to stage II + III, adjusting for age, sex, geographical area, and incidence year. Proportions were then used to estimate incidence rate ratios (IRR) by stage for screened subjects at the first and at subsequent rounds vs. unscreened subjects, applying the expected changes in overall incidence during screening phases. 11,663 cancers were included: 5965 in not-invited and 5,698 in invited subjects, 3,425 of whom attendees. Compared to not-invited, invited subjects had RRR 2.04 (95% CI: 1.84; 2.46) of stage I and RRR 0.77 (95% CI: 0.69; 0.87) of stage IV. Differences were stronger comparing attendees vs. nonattendees. Interval cancers were more frequently stage I compared to non-invited (RRR 1.54; 95% CI: 1.15; 2.04), but there was no difference for stage IV. IRRs in screened at first round vs. unscreened were 4.6 (95% CI: 4.2; 5.1), 1.4 (95% CI: 1.3; 1.5) and 0.7 (95% CI: 0.6; 0.9) for stages I, II + III and IV, respectively; in the following rounds the IRRs of screened vs. unscreened were 1.4 (95% CI: 1.2; 1.6), 0.8 (95% CI: 0.7; 0.9) and 0.3 (95% CI: 0.1; 0.4) for stages I, II + III and IV, respectively. FIT screening reduces the incidence of metastatic cancers by about 70% after the first round.
- Published
- 2019